Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor T-cell (CAR T) therapy has advanced treatment for B-cell lymphoma (BCL), but >50% of patients relapse. Predicting clinical outcomes based on features at CAR T infusion remains unclear, and most trials lack racial diversity, limiting understanding of its impact on outcomes. To address these challenges, we pooled data from 9 CAR T clinical trials, consisting of 2304 patients with BCL. The nature of this data set, made available through the Medidata Clinical Cloud, represents a large set of patient-level data aggregated over 9 clinical trials that has not been previously analyzed in this manner. Of the 2304 patients, 395 (17.1%) failed screening, and 1637 were assigned CAR T; 151 (9.22%) did not receive treatment due to adverse events, disease progression, or death, with only 12% surviving at 1 year. For treated patients, we analyzed 2 cohorts: large BCL (LBCL, n = 958) and indolent BCL (iBCL, n = 349). Multivariate Cox models revealed that low performance status and high tumor burden (Eastern Cooperative Oncology Group ≥2, bulky disease, bridging therapy) negatively affected overall survival (OS) and progression-free survival (PFS) in LBCL, whereas age and shorter time from diagnosis to infusion negatively impacted OS and PFS in iBCL. Despite the underrepresentation of non-White groups across all trial phases, the feasibility and effectiveness of CAR T therapy were consistent across racial and ethnic groups.
No takes yet. Share an insight, caveat, or question.
Kho et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: